A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets ...

the researchers believe that the positive changes in brain volume are likely due to advancements in healthcare and education ...

Brain cells become damaged and die when dementia ... "Our results indicate that ICV, white matter volume, and hippocampal ...

BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today announced the clinical development plan to ...

high quality recombinant protein which is administered via ICV injection to bypass the blood brain barrier. GC Biopharma developed the first ICV administered enzyme replacement therapy (ERT ...